GlassScriptPhysician profile
Robert J Donohue
NPI 1306871595
$3,050.63
in general payments reported to CMS, 2019-2025
28 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $31.31 · 2021: $186 · 2022: $78.78 · 2023: $142 · 2024: $1,023 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $910.45 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $332.61 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $213.31 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $204.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.49 | 2024-2025 | Jardiance |
| Abbott Laboratories | $130.38 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $124.74 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $116.31 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $104.95 | 2025 | |
| Amgen INC. | $99.41 | 2024-2025 | Evenity, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $98.21 | 2024-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $70.94 | 2022-2024 | Ingrezza |
| Viatris Specialty LLC | $60.01 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $51.83 | 2024-2025 | |
| Verona Pharma, INC. | $46.54 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.85 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $30.75 | 2025 | Nexletol |
| Ibsa Pharma INC. | $30.39 | 2024-2025 | Licart, Tirosint, Flector |
| Renalytix Ai, INC. | $29.93 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $26.25 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $26.05 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.36 | 2025 | Xifaxan |
| Lundbeck LLC | $20.29 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $20.18 | 2024 | Heplisav-B |
| Mylan Specialty L.P. | $19.29 | 2024 | Yupelri |
| Amneal Pharmaceuticals LLC | $16.45 | 2025 | Unithroid |
| E.R. Squibb & Sons, L.L.C. | $16.20 | 2024 | Camzyos |
| Biohaven Pharmaceuticals, INC. | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Donohue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.